Entrada Therapeutics, Inc. Stock Price, News & Analysis

Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, at 3:55 PM ET. This event highlights Entrada's commitment to revolutionizing medicine through its Endosomal Escape Vehicle (EEV^TM) therapeutics, targeting previously inaccessible intracellular diseases. The chat will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days post-event.

Entrada Therapeutics (Nasdaq: TRDA) reported financial results for Q3 2022, with a net loss of $25.1 million compared to $14.4 million in Q3 2021. As of September 30, 2022, the company had $216 million in cash and equivalents, projected to fund operations into 2H 2024. The company is on track to submit an IND for ENTR-601-44 for Duchenne muscular dystrophy by Q4 2022 and plans to initiate a single ascending dose study in 2023. R&D expenses rose to $19 million from $10.5 million a year prior, driven by increased preclinical study investments.

Entrada Therapeutics (Nasdaq: TRDA) announced that Nathan Dowden, Chief Operating Officer, will virtually present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be accessible starting September 12, 2022, at 7:00 a.m. Eastern Time on the company's website. A replay will be available for 90 days after the event. Entrada focuses on Endosomal Escape Vehicle (EEV™) therapeutics for treating diseases including Duchenne muscular dystrophy and myotonic dystrophy.

Entrada Therapeutics (Nasdaq: TRDA) announced that it is on track to submit an Investigational New Drug (IND) application for ENTR-601-44, targeting Duchenne muscular dystrophy (DMD), in Q4 2022. The company holds $244 million in cash and equivalents, ensuring a cash runway into 2H 2024. R&D expenses surged to $16.2 million from $6.8 million year-over-year, with a net loss of $23.2 million for Q2 2022. Entrada also presented promising preclinical data for its therapeutic candidates and initiated collaborations aimed at accelerating developments in neuromuscular disease treatments.

Entrada Therapeutics (Nasdaq: TRDA) has announced a collaboration with the Myotonic Dystrophy Clinical Research Network (DMCRN) to support the END-DM1 study, which aims to understand disease progression in myotonic dystrophy type 1 (DM1). This non-interventional study will provide critical data for future clinical trials. Entrada's clinical candidate, ENTR-701, is being developed to potentially treat DM1, with new preclinical data indicating improved therapeutic effects in mouse models. The company plans to file an IND application for ENTR-701 in 2023.

Entrada Therapeutics (Nasdaq: TRDA) announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald, previously the Vice President of Corporate Communications and Investor Relations, will report to Dipal Doshi, President and CEO. Her extensive experience in biopharmaceutical communications and stakeholder engagement supports Entrada's focus on developing Endosomal Escape Vehicle (EEV™) therapeutics, particularly for neuromuscular diseases like Duchenne muscular dystrophy. The company is transitioning into a clinical stage entity this year.

Entrada Therapeutics (Nasdaq: TRDA) announced its participation at the William Blair Biotech Focus Conference in New York on July 12-13, 2022. A fireside chat featuring Dipal Doshi and Natarajan Sethuraman will be available for viewing starting July 11, 2022, at 9:00 a.m. ET on the company’s website, with a 90-day replay. Entrada focuses on developing Endosomal Escape Vehicle (EEV™) therapeutics to target previously inaccessible intracellular sites, targeting diseases like Duchenne muscular dystrophy and myotonic dystrophy.

Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company focused on advancing Endosomal Escape Vehicle (EEV™) therapeutics, announced its participation in the Goldman Sachs Global Healthcare Conference. The event will feature a fireside chat with President and CEO Dipal Doshi on June 14, 2022, at 2:40 p.m. PT in Rancho Palos Verdes, CA. A live webcast will be available on the company’s website, with a replay accessible for 90 days afterward.

Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its second clinical candidate, ENTR-701, aimed at treating myotonic dystrophy type 1. The company is on track to submit an Investigational New Drug application for ENTR-601-44, targeting Duchenne muscular dystrophy, in Q4 2022. As of March 31, 2022, Entrada has $263.9 million in cash and equivalents, projecting sufficient funds to support operations into the second half of 2024. However, the first quarter of 2022 reported a net loss of $21.7 million, significantly higher than the $8.4 million loss in Q1 2021.